background
studi
aim
investig
possibl
serum
protein
chang
endotoxin
administr
healthi
cholinetr
calv
use
proteom
result
expect
contribut
understand
pathophysiolog
mechan
endotoxemia
benefici
effect
cholin
administr
clinic
situat
method
healthycalv
n
divid
group
control
cholin
treat
c
lipopolysaccharid
administ
lp
lp
c
control
calv
receiv
nacl
inject
calv
c
lp
c
group
receiv
cholin
chlorid
mgkgiv
endotoxin
lp
inject
calv
lp
lp
c
group
serum
sampl
collect
treatment
differenti
express
protein
foldchang
rel
control
identifi
lcmsm
result
lp
administr
protein
increas
protein
decreas
within
h
compar
control
lp
group
signific
increas
serum
level
ragul
complex
protein
protein
transcript
factor
maff
corticosteroid
bind
globulin
regul
fold
compar
lp
group
lp
c
group
fibrinogen
gammabchain
antithrombin
upregul
hemopexin
histon
downregul
cholin
treatment
attenu
actin
alpha
cardiac
overexpress
lp
conclus
lp
administr
produc
chang
serum
protein
associ
lipid
metabol
immun
inflammatori
respons
protein
bindingtransport
cell
adhes
venou
thrombosi
cardiac
contractil
blood
coagul
administr
cholin
associ
chang
protein
relat
benefici
effect
clinic
situat
endotoxemia
defin
presenc
endotoxin
blood
situat
occur
gramneg
bacteri
infect
liber
endotoxin
lipopolysaccharid
lp
rapid
growth
result
fact
gramneg
sepsi
associ
high
mortal
rate
despit
comprehens
treatment
intens
care
patient
studi
underway
regard
understand
complex
pathophysiolog
mechan
endotoxemia
describ
criteria
earli
diagnosi
develop
new
treatment
approach
order
decreas
mortal
intraven
cholin
administr
show
benefici
effect
treatment
endotoxemia
variou
speci
dog
rat
benefici
effect
intraven
cholin
treatment
report
associ
activ
effer
vagu
nervebas
cholinerg
antiinflammatori
pathway
increas
nicotin
cholinerg
neurotransmiss
follow
enhanc
acetylcholin
releas
cholin
howev
possibl
chang
serum
protein
cholin
treatment
produc
studi
proteom
analysi
allow
simultan
analysi
thousand
protein
sampl
could
facilit
identif
new
biomark
use
diagnosi
prognosi
sepsisendotoxemia
thu
proteom
analys
grow
trend
human
veterinari
medicin
particular
proteom
studi
allow
identifi
new
protein
chang
endotoxemia
know
function
new
protein
new
mechan
involv
endotoxemia
could
elucid
therefor
increas
knowledg
pathophysiolog
light
previou
find
hypothes
benefici
effect
cholin
administr
endotoxem
patient
could
mediat
chang
concentr
select
serum
protein
therefor
object
studi
evalu
possibl
chang
occur
serum
protein
proteom
analysi
endotoxin
administr
healthi
cholinetr
calv
healthi
holstein
calv
week
age
kg
mean
weight
n
use
present
studi
health
statu
evalu
clinic
haematolog
serum
biochem
analys
calv
neg
bovin
herp
viru
bovin
leucosi
viru
brucellosi
bovin
viral
diarrhea
foot
mouth
diseas
infecti
bovin
rhinotrach
paratuberculosi
tuberculosi
test
commerci
elisa
kit
idvet
diagnost
grabel
franc
calv
random
equal
group
control
cholin
treat
c
lipopolysaccharid
administ
lp
lp
c
calv
control
group
inject
nacl
salin
ml
iv
twice
interv
min
c
group
receiv
cholin
chlorid
mgkg
dissolv
ml
salin
iv
min
nacl
administr
ml
iv
lp
group
endotoxin
lp
inject
dissolv
ml
normal
salin
iv
calv
follow
min
later
intraven
inject
normal
salin
lp
c
group
endotoxin
inject
follow
min
later
cholin
chlorid
inject
dose
describ
lp
c
group
respect
routin
clinic
examin
perform
baselin
h
treatment
score
system
adapt
previou
paper
use
evalu
clinic
statu
studi
paramet
score
minimum
point
mean
normal
maximum
point
mean
sever
affect
order
analys
differ
protein
express
cours
studi
three
serum
sampl
time
point
treatment
obtain
protein
profil
serum
sampl
analys
lcmsm
method
albumin
deplet
serum
sampl
done
albumin
deplet
spin
column
pierc
thermo
scientif
igg
albumindeplet
serum
sampl
also
deplet
albuminigg
remov
kit
pierc
thermo
scientif
remain
serum
protein
concentr
sampl
extract
enzymat
digest
peptid
result
peptid
subject
nanouplcesiqtofm
system
nanoultraperform
lc
esi
quadrupol
tof
ms
water
applic
data
independ
acquisit
method
also
known
ms
e
previous
describ
detail
minimum
technic
replic
sampl
use
analysi
proteom
data
search
review
databas
includ
protein
sequenc
bo
tauru
intern
standard
enolas
saccharomyc
cerevisia
obtain
uniprot
htpp
wwwuniprotorg
previous
describ
silico
paramet
quantit
differ
protein
differ
time
point
calcul
use
progenesi
lcm
softwar
nonlinear
dynam
cholin
chlorid
endotoxin
e
coli
lipopolysaccharid
lp
serotyp
purchas
sigma
chemic
co
st
loui
missouri
usa
result
express
mean
sem
data
evalu
oneway
analysi
varianc
repeat
measur
follow
tukey
test
pairwis
comparison
clinic
score
compar
nonparametr
test
friedman
repeat
measur
anova
rank
p
valu
less
consid
signific
clinic
find
present
addit
file
fig
briefli
cholin
induc
decreas
heart
respiratori
rate
compar
control
anim
lp
administr
increas
bodi
temperatur
heart
respiratori
rate
compar
baselin
sever
chang
lp
c
treatment
lower
p
calv
treat
lp
two
calv
die
h
lp
one
h
lp
c
calv
control
cholin
group
surviv
end
studi
protein
express
differ
among
experiment
group
differ
time
point
min
h
shown
tabl
detail
includ
numer
valu
quantit
analysi
obtain
progenesi
lcm
softwar
shown
addit
file
total
protein
identifi
across
serum
sampl
proteom
analysi
lp
administr
protein
increas
wherea
protein
decreas
within
h
compar
control
tabl
lp
group
dramat
increas
fold
h
ragul
complex
protein
follow
protein
show
chang
rang
fold
neg
elong
factor
e
h
bind
protein
argininosuccin
lyas
membran
primari
amineoxidas
h
follow
lp
administr
moder
decreas
fold
chang
observ
protein
serpin
min
vitamin
bind
protein
vdbp
inter
alpha
trypsin
inhibitor
heavi
chain
itih
h
apolipoprotein
iv
apoaiv
glycoprotein
serotransferrin
b
c
fig
clinic
paramet
temperatur
bc
heart
respiratori
rate
total
clinic
score
salin
cholin
lp
lp
cholin
group
calv
inject
iv
salin
ml
salin
contain
cholin
chlorid
mgkg
five
minut
first
iv
treatment
calv
receiv
endotoxin
lp
ml
normal
salin
measur
perform
immedi
first
iv
treatment
h
h
salin
cholin
lp
lp
cholin
treatment
point
repres
mean
sem
six
determin
p
p
p
compar
baselin
p
p
compar
salin
group
compar
lp
group
lp
c
group
membran
primari
amin
oxidas
fibrinogen
gamma
b
chain
antithrombin
prothrombin
markedli
upregul
isoform
membran
primari
amin
oxidas
hemopexin
markedli
downregul
actin
alpha
cardiac
express
increas
h
fold
lp
lp
c
group
compar
control
magnitud
increas
actin
alpha
cardiac
lower
h
lp
c
group
lp
group
compar
control
follow
cholin
administr
number
protein
primari
amin
oxidas
serpin
upregul
other
lysosom
associ
membran
downregul
differ
time
point
studi
studi
experiment
model
consist
induct
endotoxemia
lp
administr
calv
chosen
calv
sensit
lp
therefor
expect
chang
associ
lp
well
treatment
easier
detect
anim
model
clinic
chang
occur
lp
treatment
experiment
model
calv
show
similar
result
experiment
human
anim
studi
sepsisendotoxemia
knowledg
studi
describ
first
time
protein
upregul
protein
downregul
endotoxemia
calv
role
alter
protein
highlight
one
protein
dramat
upregul
ragul
complex
protein
protein
known
involv
amino
acid
sens
activ
signal
complex
promot
cell
growth
respons
growth
factor
energi
level
amino
acid
previou
studi
report
sever
immunolog
defect
affect
immun
human
primari
immunodefici
syndrom
associ
reduc
level
henc
elev
serum
level
ragul
complex
studi
may
associ
host
respons
increas
macrophag
activ
enhanc
adapt
immun
respons
lp
thu
ragul
complex
may
repres
new
earli
diagnost
marker
detect
inflamm
calv
due
dramat
overexpress
shortli
lp
treatment
anoth
protein
significantli
increas
calv
lp
administr
protein
stimulatori
activ
lymphokineactiv
natur
killer
cell
also
stimul
secret
mani
cytokin
interleukin
peripher
blood
mononuclear
cell
play
contributori
role
inflamm
studi
upregul
express
may
associ
limit
ongo
inflamm
respons
lp
immun
modulatori
activ
addit
overexpress
may
consid
host
respons
neutral
harm
effect
releas
lpsstimul
cell
produc
heighten
level
inflammatori
mediat
result
tissu
damag
ultim
organ
failur
characterist
sepsi
hand
critic
role
develop
venou
thrombosi
increas
surviv
cancer
cell
bloodstream
indic
probabl
involv
pathophysiolog
respons
differ
patholog
condit
transcript
factor
maff
cbg
associ
interleukin
regul
protect
effect
situat
cell
stress
coagul
cascad
activ
sever
ill
possibl
reason
regul
protein
found
studi
may
excess
use
neutral
detriment
effect
lp
acut
phase
reaction
proteas
lpsactiv
leukocyt
trigger
tissu
organ
damag
enhanc
nonspecif
proteolysi
plasma
clot
factor
patient
sever
sepsi
one
exampl
leukocyt
elastas
involv
progress
complic
patient
sepsi
present
studi
regul
calv
lp
probabl
due
extend
secret
elastas
therebi
protein
may
part
regulatori
system
control
acut
inflamm
calv
similar
find
circul
itih
protein
level
found
lower
patient
sever
sepsi
healthi
volunt
confirm
previou
find
dog
rat
found
present
studi
cholin
treatment
improv
clinic
sign
associ
lp
studi
includ
larger
number
calv
need
evalu
cholin
treatment
could
reduc
mortal
rate
clinic
condit
endotoxemia
studi
dog
show
benefici
effect
cholin
treatment
might
relat
inhibit
synthesi
prevent
hepatoren
injuri
attenu
chang
serum
butrylcholinesteras
activ
downregul
protein
cholin
treatment
prothrombin
ragul
complex
involv
coagul
develop
dic
therefor
decreas
protein
could
associ
prevent
effect
cholin
treatment
develop
coagulopathi
describ
previous
dog
addit
downregul
histon
cholin
treatment
would
relat
protect
effect
cholin
histon
protein
mainli
report
exhibit
cytotox
releas
extracellular
fluid
respons
sever
stress
inflammatori
challeng
like
sepsi
mediat
excess
overwhelm
cell
damag
death
hemopexin
hx
mainli
express
app
liver
inflamm
studi
hx
overexpress
may
relat
antioxid
role
facilit
tissu
repair
respons
lp
cholin
treatment
decreas
hx
overexpress
calv
lp
probabl
relat
reduct
bodi
antioxid
need
due
reduct
tissu
damag
produc
cholin
increas
found
cholin
administr
could
relat
protect
effect
describ
saa
inhibit
tnf
lp
well
platelet
aggreg
addit
correl
cholinesteras
found
therefor
link
respons
cholin
administr
could
hypothes
cholin
treatment
attenu
overexpress
contractil
protein
actin
alpha
cardiac
h
lp
indic
protect
effect
cholin
treatment
sepsisinduc
myocardi
dysfunct
simd
simd
wellrecogn
manifest
organ
dysfunct
patient
sepsi
calv
endotoxemia
lpsinduc
overexpress
may
contribut
myocardi
dysfunct
endotoxemia
probabl
due
impair
sarcomer
integr
observ
overexpress
may
due
decreas
thymosin
express
sinc
thymosin
play
import
role
organ
cytoskeleton
bind
sequest
actin
monom
result
inhibit
actin
polymer
although
pilot
studi
made
small
sampl
size
therefor
result
taken
caution
could
conclud
base
experiment
model
follow
lp
administr
chang
select
serum
protein
associ
variou
biolog
process
lipid
metabol
immun
inflammatori
respons
protein
bind
transport
cell
adhes
venou
thrombosi
cardiac
contract
blood
coagul
addit
cholin
administr
associ
chang
serum
concentr
select
serum
protein
would
relat
benefici
effect
clinic
situat
find
would
reinforc
effect
cholin
administr
treatment
endotoxemia
howev
studi
need
confirm
result
due
small
sampl
size
studi
addit
would
interest
evalu
effect
cholin
treatment
combin
drug
steroid
nonsteroid
antiinflammatori
drug
addit
file
clinic
paramet
temperatur
heart
respiratori
rate
total
clinic
score
group
xlsx
kb
